Fact Sheet: EtO Sterilization Prevents Infection

Join Kearney as they explore how medtech organizations are using AI to transform product development and accelerate innovation.

Millions of patients’ lives are improved every day because of advancements in medical technology. But too often, gaps in coverage and access prevent patients from benefiting from the safe, effective, and innovative technologies that can help detect disease earlier, improve treatment, and support better outcomes. 

That is why AdvaMed’s 2026 Patients First Agenda focuses on supporting policies that put patients at the center of health care. Across the country, AdvaMed works alongside patient advocacy group partners to help address gaps in access and coverage for critical medical technologies and bring innovative care to patients and families when they need it most.

Explore ASC growth trends, buyer dynamics & go-to-market strategies for medtech manufacturers in this webinar with Alexander Group.

AdvaMed’s feedback on the CEIVD draft outlines targeted recommendations to improve clarity in clinical evidence expectations for IVD devices, including more precise terminology, alignment with global frameworks, and clearer distinctions between real-world data and evidence.

AdvaMed outlines recommendations to ensure EPA’s proposed ethylene oxide (EtO) emissions standards protect public health while maintaining access to life-saving medtech.

Washington, D.C.—AdvaMed, the Medtech Association, the world’s biggest trade association representing medtech innovators, welcomed Senate introduction of the bipartisan Medical Device Electronic Labeling Act (S. 4519), which would allow medtech instructions for use to be provided electronically, with paper copies being available upon request.

IRVINE, Calif., May 7, 2026 /PRNewswire/ — Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Glean® Abdominal Sensor. This new sensor expands the capabilities of the Glean® Urodynamics System to include multi-channel urodynamic studies. This comprehensive system enables wireless, catheter-free ambulatory urodynamics designed to support clinical decision making for patients with LUTD and other urological conditions.

PALO ALTO, CA, UNITED STATES, May 4, 2026 / EINPresswire.com / — Biopharma and medtech companies face a years-long process to get their products approved. Drug and device makers navigate a full spectrum of FDA and global regulatory frameworks to move innovation forward.